Genmab Shares Climb on Positive Blood-Cancer Drug Study Results
Genmab shares jumped 8.3% after the company and partner AbbVie announced positive late-stage clinical trial results for their Epkinly drug in a common type of lymphoma. The drug helped extend the time patients lived without their disease worsening.